The prognostic significance of p53, p27kip1, p21waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: A clinicopathological and immunohistochemical study of 121 Arab patients

Journal of Surgical Oncology

Volumn 91, Issue 4, 2005, Pages 243-252

  Al Moundhri, M S ^a   Nirmala, V ^a   Al Hadabi, I ^a   Al Mawaly, K ^a   Burney, I ^a   Al Nabhani, M ^a   Thomas, V ^a   Ganguly, S S ^a   Grant, C ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Arabs; Gastric cancer; HER 2 neu; Immunohistochemistry; Ki67 antigen; p21; p27kip1; p53; Prognosis; Stomach

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; ARAB; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ARABS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 24644467632     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20324     Document Type: Article

References (66)

1. Roukos DH: Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243-255.
2. Ministry of Health, Sultanate of Oman: Cancer incidence in Oman. 2001:28-31.
3. McCulloch P, Taggart T, Ochiai A, et al.: c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol 1997;23:304-309.
4. Livingstone JI, Yasui W, Tahara E, et al.: Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study. Br J Cancer 1995;72:976-980.
5. Gill S, Shah A, Le N, et al.: Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 2003;21:2070-2076.
6. Chau I, Norman AR, Cunningham D, et al.: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403.
7. Yokota T, Ishiyama S, Saito T, et al.: Lymph node metastasis as a significant prognostic factor in gastric cancer: A multiple logistic regression analysis. Scand J Gastroenterol 2004;39:380-384.
8. Dicken BJ, Saunders LD, Jhangri GS, et al.: Gastric cancer: Establishing predictors of biologic behavior with use of population-based data. Ann Surg Oncol 2004;11:629-635.
9. Fenoglio-Preiser CM, Wang J, Stemmermann GN, et al.: TP53 and gastric carcinoma: A review. Hum Mutat 2003;21:258-270.
10. Wiksten JP, Lundin J, Nordling S, et al.: The prognostic value of p27 in gastric cancer. Oncology 2002;63:180-184.
11. Liu XP, Tsushimi K, Tsushimi M, et al.: Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: Its relationships with cell proliferation activity and prognosis. Cancer Lett 2001;170:183-189.
12. Garcia I, Vizoso F, Martin A, et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003;10:234-241.
13. Zolota V, Batistatou A, Tsamandas AC, et al.: Immunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: A clinicopathologic study. Int J Gastrointest Cancer 2002;32:83-89.
14. Michieli P, Chedid M, Lin D, et al.: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.
15. Lee KE, Lee HJ, Kim YH, et al.: Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173-179.
16. Liu XP, Tsushimi K, Tsushimi M, et al.: Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int 2001;51:440-444.
17. Feakins RM, Mulcahy HE, Quaglia A, et al.: p27(Kip1) loss does not predict survival in patients with advanced gastric carcinoma. Cancer 2000;89:1684-1691.
18. Migaldi M, Zunarelli E, Sgambato A, et al.: P27Kip1 expression and survival in NO gastric carcinoma. Pathol Res Pract 2001; 197:231-236.
19. Kaye PV, Radebold K, Isaacs S, et al.: Expression of p53 and p21waf1/cip1 in gastric carcinoma: Lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol 2000;26:39-43.
20. Liu XP, Kawauchi S, Oga A, et al.: Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 2001;39:603-610.
21. Pinto-de-Sousa J, David L, Almeida R, et al.: c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002;10:247-256.
22. Garcia I, del Casar JM, Corte MD, et al.: Epidermal growth factor receptor and c-erbB-2 contents in unresectable (UICC R1 or R2) gastric cancer. Int J Biol Markers 2003; 18:200-206.
23. Ghaderi A, Vasei M, Maleck-Hosseini SA, et al.: The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 2002;8:252-256.
24. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
25. Yonemura Y, Ooyama S, Sugiyama K, et al.: Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer 1990;65:1130-1134.
26. Hosaka N, Ichikawa Y, Ishikawa T, et al.: Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer. Anticancer Res 2001;21:229-235.
27. Greene FLP, DL, Fleming ID, et al.: AJCC cancer staging handbook. Springer, 2002.
28. al-Lawati JA, Santhosh-Kumar CR, Mohammed AJ, et al.: Cancer incidence in Oman, 1993-1997. East Mediterr Health J 1999;5: 1035-1041.
29. alwati JA: Gastric cancer. Oman national cancer registery 2002; 34-38.
30. Bani-Hani KE: Clinicopathological comparison between young and old age patients with gastric adenocarcinoma. Int J Gastrointest Cancer 2005;35:43-52.
31. Kim DY, Joo JK, Ryu SY, et al.: Clinicopathologic characteristics of gastric carcinoma in elderly patients: A comparison with young patients. World J Gastroenterol 2005;11:22-26.
32. Koea JB, Karpeh MS, Brennan MF: Gastric cancer in young patients: Demographic, Clinicopathological, and prognostic factors in 92 patients. Ann Surg Oncol 2000;7:346-351.
33. Yao JC, Schnirer II, Reddy S, et al.: Effects of sex and racial/ ethnic group on the pattern of gastric cancer localization. Gastric Cancer 2002;5:208-212.
34. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.
35. Thong-Ngam D, Tangkijvanich P, Mahachai V, et al.: Current status of gastric cancer in Thai patients. J Med Assoc Thai 2001; 84:475-482.
36. Kandasami P, Tan WJ, Norain K: Gastric cancer in Malaysia: The need for early diagnosis. Med J Malaysia 2003;58:758-762.
37. Koong HN, Chan HS, Nambiar R, et al.: Gastric cancers in Singapore: Poor prognosis arising from late presentation. Aust N Z J Surg 1996;66:813-815.
38. Kong SH, Park do J, Lee HJ, et al.: Clinicopathologic features of asymptomatic gastric adenocarcinoma patients in Korea. Jpn J Clin Oncol 2004;34:1-7.
39. Noda H, Maehara Y, Irie K, et al.: Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAF1/CIP1 in early gastric carcinoma. Cancer 2001;92:1828-1835.
40. Aoyagi K, Koufuji K, Yano S, et al.: The expression of p53, p21 and TGF beta 1 in gastric carcinoma. Kurume Med J 2003;50: 1-7.
41. Yokozaki H, Yasui W, Tahara E: Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 2001;204:49-95.
42. Yokota T, Ishiyama S, Saito T, et al.: Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res 2002;22:3673-3677.
43. Bando E, Kojima N, Kawamura T, et al.: Prognostic value of age and sex in early gastric cancer. Br J Surg 2004;91:1197-1201.
44. Kim JH, Uhm HD, Gong SJ, et al.: Relationship between p53 overexpression and gastric cancer progression. Oncology 1997; 54:166-170.
45. Chen BF, Marrogi AJ, Freeman SM, et al.: Gastric carcinoma: Recent issues in prognostic factors. J La State Med Soc 1995; 147:138-145.
46. Muller W, Borchard F: Prognostic influence of p53 expression in gastric cancer. J Pathol 1996;178:255-258.
47. Tang H, Hokita S, Che X, et al.: Comparison of p53 expression in proximal and distal gastric cancer: Histopathologic correlation and prognostic significance. Ann Surg Oncol 1997;4:470-474.
48. Sanz-Ortega J, Steinberg SM, Moro E, et al.: Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000;15:455-462.
49. Ranzani GN, Luinetti O, Padovan LS, et al.: p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 1995;4:223-231.
50. Muller W, Grabsch H, Takeno S, et al.: Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer. Anticancer Res 2000;20:1787-1792.
51. Saragoni L, Morgagni P, De Manzoni G, et al.: [Expression of p27 and proliferative (MIB-1), mitotic (MI) and apoptotic indices in early-phase (EGF) gastric carcinoma. Results of a study by the Italian Gastric Cancer Research Group (IRGGC)]. Pathologica 2003;95:22-30.
52. Kim DH, Lee HI, Nam ES, et al.: Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2000;36: 245-251.
53. Kwon OJ, Kang HS, Suh JS, et al.: The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res 1999;19:4215-4220.
54. Nitti D, Belluco C, Mammano E, et al.: Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 2002;81: 167-175; discussion 175-166.
55. Sgambato A, Migaldi M, Leocata P, et al.: Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in NO gastric carcinomas. Cancer 2000;89:2247-2257.
56. Okuyama T, Maehara Y, Kabashima A, et al.: Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology 2002;63:353-361.
57. Jang SJ, Ahn MJ, Paik SS, et al.: Expression of cyclin dependent kinase inhibitor p21WAF1 alone and in combination with p27KIP1 shows prognostic value in gastric carcinoma. J Korean Med Sci 1998;13:369-376.
58. Mateo M, Saez A, Sanchez-Beato M, et al.: Expression of p21 WAF1/CIP1 in fetal and adult tissues: Simultaneous analysis with Ki67 and p53. J Clin Pathol 1997;50:645-653.
59. Fredersdorf S, Burns J, Milne AM, et al.: High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. PNAS 1997; 94:6380-6385.
60. Bai M, Tsanou E, Agnantis NJ, et al.: Proliferation profile of classical Hodgkins lymphomas. Increased expression of the protein cyclin D2 in Hodgkins and Reed-Sternberg cells. Mod Pathol 2004;17:1338-1345.
61. Heng JD, Werness BA, Babb JS, et al.: Paradoxical Correlations of Cyclin-dependent Kinase Inhibitors p21 waf1/cip1 and p27kip1 in Metastatic Colorectal Carcinoma. Clin Cancer Res 1999;5: 1057-1062.
62. Polyak K, Kato J, Solomon M, et al.: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
63. Pinto-de-Sousa JSF, David L, Leitao D, et al.: Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 2004;44:323-331.
64. Wang YL, Sheu BS, Yang HB, et al.: Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma-emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 2002;49:1172-1176.
65. Nabeya Y, Loganzo F, Jr., Maslak P, et al.: The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995;64:37-46.
66. Cascinu S, Graziano F, Del Ferro E, et al.: Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998;83:1917-1922.